The role of the renin-angiotensin system in the development of cardiovascular disease.
about
Erythropoietin and renin as biological markers in critically ill patients.Adipocyte-derived leucine aminopeptidase genotype and response to antihypertensive therapyStructural characterization of angiotensin I-converting enzyme in complex with a selenium analogue of captoprilInsights into Substrate Specificity and Metal Activation of Mammalian Tetrahedral Aspartyl AminopeptidaseCardiac remodelling and RAS inhibitionPolychlorinated biphenyls and links to cardiovascular diseaseThe involvement of angiotensin type 1 and type 2 receptors in estrogen-induced cell proliferation and vascular endothelial growth factor expression in the rat anterior pituitaryAngiotension II receptor 1 blocker modifies the expression of apoptosis-related proteins and transforming growth factor-beta1 in prostate tissue of spontaneously hypertensive ratsAngiotensin II reduces cardiac AdipoR1 expression through AT1 receptor/ROS/ERK1/2/c-Myc pathwayAdditive antiproteinuric effect of enalapril and losartan in children with hemolytic uremic syndrome.Impaired kidney function and atrial fibrillation in elderly subjects.Management of Hypertension Using Olmesartan Alone or in CombinationThe vascular renin-angiotensin system contributes to blunted vasodilation induced by transient high pressure in human adipose microvesselsAdvanced glycation end products activate a chymase-dependent angiotensin II-generating pathway in diabetic complications.The impact of age-related dysregulation of the angiotensin system on mitochondrial redox balanceLocal renin-angiotensin systems and their interactions with extra-adrenal corticosteroid production.Renin-angiotensin system gene polymorphisms among Saudi patients with coronary artery disease.ACE2-Ang (1-7) axis is induced in pressure overloaded rat model.Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular riskAngiotensin receptor blockers as anti-hypertensive treatment for patients with diabetes mellitus: meta-analysis of controlled double-blind randomized trials.The implications of physical activity in patients with chronic heart failure.Evaluation of Left Ventricle Function by Regional Fractional Area Change (RFAC) in a Mouse Model of Myocardial Infarction Secondary to Valsartan Treatment.Sex-specific effects of prenatal low-protein and carbenoxolone exposure on renal angiotensin receptor expression in ratsAngiotensin-(1-7)-mediated signaling in cardiomyocytes.ARBs and target organ protection. Exploring benefits beyond their antihypertensive effects.Genetic polymorphisms and heart failure.Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapyRelation of renal function to risk for incident atrial fibrillation in women.Olmesartan vs ramipril in the treatment of hypertension and associated clinical conditions in the elderly: a reanalysis of two large double-blind, randomized studies at the light of the most recent blood pressure targets recommended by guidelines.ACE inhibition prevents diastolic Ca2+ overload and loss of myofilament Ca2+ sensitivity after myocardial infarction.The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy.RAS inhibition in hypertension.Effective treatment of hypertension by recombinant Lactobacillus plantarum expressing angiotensin converting enzyme inhibitory peptideNeuromarkers of the common angiotensinogen polymorphism in healthy older adults: A comprehensive assessment of white matter integrity and cognitionAngiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice.Effective treatment of hypertension by AT(1) receptor antagonism: the past and future of telmisartan.Cisplatin-induced nephrotoxicity alters blood pressure response to angiotensin II administration in rats.ROS and endothelial nitric oxide synthase (eNOS)-dependent trafficking of angiotensin II type 2 receptor begets neuronal NOS in cardiac myocytes.Angiotensin-converting enzyme 2 activation improves endothelial functionRU28318, an aldosterone antagonist, in combination with an ACE inhibitor and angiotensin receptor blocker attenuates cardiac dysfunction in diabetes.
P2860
Q24799878-B86E17A7-EA37-4363-B258-414EA1EE6F32Q24803588-35EA062C-2EEB-4A3A-AF2C-AE404B4015A2Q27671388-1AD330EC-7156-413E-AE73-FD3B415E915BQ27677420-2031D48A-10C4-48A2-9E65-E6F5041E734FQ28076749-C7142501-B777-4B64-B8DA-A12D96687BDBQ28391417-587772BF-AB80-47B0-8357-1D2E8FA86D0FQ28569919-A5B0706C-BD41-4B73-B13B-91E7B17FFDE0Q28571464-EAE67802-BAEC-4A45-A315-57BB9F0A60DFQ28574928-21E2F0F7-4914-4ACC-A729-19D81642A4B5Q33404886-A31BFC68-B7F8-4BDD-8F0C-8CA53098396EQ33635948-B4349710-A9FC-4E82-A1A6-5F1F3A95CA31Q33734043-9767E842-6946-47F3-9434-B24DA787AB4BQ33840069-765582B8-679A-4C32-9D92-8160A96F9AE3Q34448452-60650F7A-8830-42A2-8EC0-2EDC1EC26475Q34562975-6B50899A-6EC1-40F5-BD58-D0B59DE2F421Q35065520-6F4B0A03-6B82-4DC0-B2F0-D431D745380CQ35320005-8F90E201-2493-4FC8-9917-453CBFF555AFQ35407065-2266CCD6-04A5-44A4-B60E-EA62CD27B5A2Q35539305-ED138F94-0DF2-4F88-83F4-16194B4B916CQ35620731-8171B16A-7D3B-43EB-93A4-F3E61DA8414CQ35660774-2371629B-8090-443A-BA36-5C44B6FC0550Q35751394-DC57B180-04C4-4A63-9A04-203B47393610Q35828294-9099DAEA-C0C4-4CE3-AB0F-CE4CC63A70D8Q35829928-F6D9D902-291A-4C63-B694-1B1A089FCBE4Q35868228-64A4457A-8766-4025-B67E-977C5B22CF04Q35951357-A5343CB0-D1E9-479E-8976-4739FD2EAE52Q36013124-CD62C8B6-7D1B-439C-B9C7-F8CFCC864F3AQ36108990-58B171AF-92D0-41E6-AFDB-FEC8E5DC4014Q36137337-4C7C5E83-2C0E-4202-AEBB-C3A07C372C79Q36320507-55B04CB8-011B-42E0-97CE-7782B0D0B538Q36362376-914034FF-FF6E-4EF7-B305-743ECD705F2CQ36362382-52974B8F-7131-401D-9E7E-5E7D258E886EQ36393679-876A2968-3BF6-4662-A08D-8A825E3A513BQ36407028-24EEB101-32B8-465D-9BA6-DB9C731A7F39Q36524275-FCBE5532-F612-4E93-B4A8-05536D10F6F6Q36642651-348AEB73-2284-4AED-91A5-D9012ED3979BQ36755727-B658E253-A457-49A5-AC5D-A9E4D609A567Q36785528-C51DCD4D-EB0E-403B-B9F9-4A744A4A086AQ37069541-B194360B-B042-4EB0-B030-5B8AF3D3F87FQ37166553-762FE90C-A20C-4BE6-88AC-B07D106B542D
P2860
The role of the renin-angiotensin system in the development of cardiovascular disease.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The role of the renin-angiotensin system in the development of cardiovascular disease.
@ast
The role of the renin-angiotensin system in the development of cardiovascular disease.
@en
The role of the renin-angiotensin system in the development of cardiovascular disease.
@nl
type
label
The role of the renin-angiotensin system in the development of cardiovascular disease.
@ast
The role of the renin-angiotensin system in the development of cardiovascular disease.
@en
The role of the renin-angiotensin system in the development of cardiovascular disease.
@nl
prefLabel
The role of the renin-angiotensin system in the development of cardiovascular disease.
@ast
The role of the renin-angiotensin system in the development of cardiovascular disease.
@en
The role of the renin-angiotensin system in the development of cardiovascular disease.
@nl
P1476
The role of the renin-angiotensin system in the development of cardiovascular disease.
@en
P2093
Thomas Unger
P304
3A-9A; discussion 10A
P356
10.1016/S0002-9149(01)02321-9
P407
P577
2002-01-01T00:00:00Z